Drug Trial Radar · NCT07923851
A Trial Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Palmoplantar Pustulosis
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2027
Study completion Mar 2029
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy and safety of SHR-1139 injection.
Conditions
- Palmoplantar Pustulosis of Adults
Interventions
SHR-1139 InjectionDrug
SHR-1139 Injection.
SHR-1139 Injection PlaceboDrug
SHR-1139 Injection Placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI)Time frame: Baseline to Day 113.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.